Comparative efficacy of systemic sequential regorafenib after sorafenib or lenvatinib treatment failure for advanced hepatocellular carcinoma: A retrospective, multi-center, real-world study

被引：0
|
作者：
Song, D. [1 ]
Zheng, L. [2 ]
Zhang, A. [1 ]
Cao, F. [1 ]
Hao, W. [1 ]
Zhao, Z. [2 ]
Zheng, J. [1 ]
Lu, D. [3 ]
机构：
[1] Univ Chinese Acad Sci, Canc Hosp, Dept Intervent Therapy, Zhejiang Canc Hosp, Hangzhou, Peoples R China
[2] Zhejiang Univ, Zhejiang Prov Key Lab Imaging Diag & Minimally In, Lishui Hosp, Lishui, Peoples R China
[3] USTC, Dept Intervent Therapy, Affiliated Hosp 1, Anhui Prov Hosp, Hefei, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2148
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1004P
引用
收藏
页码：S615 / S615
页数：1
相关论文
共 50 条
  • [1] Comparative efficacy of systemic sequential regorafenib after TACE combined with first-line targeted drugs (donafenib, sorafenib, or lenvatinib) after treatment failure for advanced hepatocellular carcinoma: A retrospective, single-center, real-world study
    Wei, Ning
    Lu, Dong
    Zhou, Chunze
    Cheng, Delei
    Zhang, Zhengfeng
    Zhang, Xingming
    Xiao, Jingkun
    Lv, Weifu
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea
    Lee, Min Jin
    Chang, Sung Won
    Kim, Ji Hoon
    Lee, Young-Sun
    Cho, Sung Bum
    Seo, Yeon Seok
    Yim, Hyung Joon
    Hwang, Sang Youn
    Lee, Hyun Woong
    Chang, Young
    Jang, Jae Young
    [J]. INVESTIGATIONAL NEW DRUGS, 2021, 39 (01) : 260 - 268
  • [3] Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea
    Min Jin Lee
    Sung Won Chang
    Ji Hoon Kim
    Young-Sun Lee
    Sung Bum Cho
    Yeon Seok Seo
    Hyung Joon Yim
    Sang Youn Hwang
    Hyun Woong Lee
    Young Chang
    Jae Young Jang
    [J]. Investigational New Drugs, 2021, 39 : 260 - 268
  • [4] The real-world systemic sequential therapy of sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea
    Lee, Yoonseok
    Chang, Sung Won
    Lee, Min-Jin
    Kim, Ji Hoon
    Bang, Soo Min
    Kim, Sehwa
    Lee, Young-Sun
    Cho, Sung Bum
    Seo, Yeon Seok
    Yim, Hyung Joon
    Hwang, Sang Youn
    Lee, Hyun Woong
    Chang, Young
    Jang., Jae Young
    [J]. JOURNAL OF HEPATOLOGY, 2020, 73 : S909 - S909
  • [5] Comparative efficacy of PD-1 inhibitors plus lenvatinib and regorafenib after lenvatinib failure for advanced hepatocellular carcinoma: a real-world study
    Renguo Guan
    Jie Mei
    Shaohua Li
    Wenping Lin
    Min Deng
    Wei Wei
    Rongping Guo
    [J]. Hepatology International, 2023, 17 : 765 - 769
  • [6] Comparative efficacy of PD-1 inhibitors plus lenvatinib and regorafenib after lenvatinib failure for advanced hepatocellular carcinoma: a real-world study
    Guan, Renguo
    Mei, Jie
    Li, Shaohua
    Lin, Wenping
    Deng, Min
    Wei, Wei
    Guo, Rongping
    [J]. HEPATOLOGY INTERNATIONAL, 2023, 17 (03) : 765 - 769
  • [7] Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study
    Chon, Young Eun
    Kim, Dong Yun
    Kim, Mi Na
    Kim, Beom Kyung
    Kim, Seung Up
    Park, Yong
    Ahn, Sang Hoon
    Ha, Yeonjung
    Lee, Joo Ho
    Lee, Kwan Sik
    Kang, Beodeul
    Kim, Jung Sun
    Chon, Hong Jae
    Kim, Do Young
    [J]. CLINICAL AND MOLECULAR HEPATOLOGY, 2024, 30 (03)
  • [8] Sorafenib Versus Lenvatinib-Based Sequential Systemic Therapy for Advanced Hepatocellular Carcinoma: A Real-World Analysis
    Leyh, Catherine
    Ehmer, Ursula
    Roessler, Daniel
    Philipp, Alexander B.
    Reiter, Florian P.
    Jeliazkova, Petia
    Jochheim, Leonie S.
    Jeschke, Matthias
    Hammig, Janina
    Ludwig, Johannes M.
    Theysohn, Jens M.
    Geier, Andreas
    Lange, Christian M.
    [J]. CANCERS, 2022, 14 (08)
  • [9] Comparison of the safety and prognosis of sequential regorafenib after sorafenib and lenvatinib treatment failure in patients with unresectable hepatocellular carcinoma: a retrospective cohort study
    Zhai, Jian
    Liu, Jianwei
    Fu, Zhigang
    Bai, Shilei
    Li, Xiaowei
    Qu, Zengqiang
    Sun, Yanfu
    Ge, Ruiliang
    Xue, Feng
    [J]. JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, 13 (03) : 1278 - 1288
  • [10] Clinical Outcomes of Sorafenib Treatment Failure for Advanced Hepatocellular Carcinoma and Candidates for Regorafenib Treatment in Real-World Practice
    Uchikawa, Shinsuke
    Kawaoka, Tomokazu
    Aikata, Hiroshi
    Kodama, Kenichiro
    Hiramatsu, Akira
    Imamura, Michio
    Chayama, Kazuaki
    [J]. HEPATOLOGY, 2018, 68 : 838A - 839A
12345